Eli Lilly (NYSE:LLY)announces that enrollment is now open for the CHALLENGE-MIG clinical trial, the first and only head-to-head trial comparing two anti-calcitonin gene-related peptide (CGRP) medicines for the preventive treatment of episodic migraine in adults.
The study is evaluating once-monthly Emgality (galcanezumab-gnlm) injection compared to Nurtec ODT (rimegepant).
The trial is expected to enroll approx. 700 adults across the U.S. with episodic migraine, and individual participation in the study can last up to 6 months.
The primary endpoint is ≥50% reduction from baseline in monthly migraine headache days across the 3-month treatment period.
Secondary endpoints include ≥75% and 100% reduction from baseline in monthly migraine headache days and quality of life improvements.